Roche opens access to pathology imaging tools to improve patient care

NEXT STORY
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
PREV STORY
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Retrophin Reports Third Quarter 2016 Financial Results

Positive top-line results from DUET announced in September; additional data to be presented at ...

author_avatar
NASDAQ Market News

Inovio Pharmaceuticals to Report Second Quarter 2016 Financial Results August 8, 2016

PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced ...

author_avatar
NASDAQ Market News

Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City

― Key opinion leaders Steven Burdette, M.D., (Professor of Medicine at Wright State University ...

author_avatar
NASDAQ Market News